Investors Failed To Plead Elements Of Their Securities Claims, Shkreli Argues

Mealey's (August 26, 2016, 9:36 AM EDT) -- SAN FRANCISCO — Dismissal of claims against former KaloBios Pharmaceuticals Inc. CEO Martin Shkreli is proper because the lead plaintiffs have failed to plead reliance and because Shkreli’s allegedly false and...
To view the full article, register now.